MustGrow Biologics (CSE: MGRO) has successfully completed a proof-of-concept for its proprietary biological non-selective bio-herbicide. The company announced this morning that its signature mustard-derived formulation has passed this proof of concept for the control of wanted pests and diseases.
The proof of concept conducted by the company demonstrated that its formulation has successfully shown that it kills 100% of weeds when applied on small weeds and weed seeds. The bio-herbicide was found to kill the target plants from the root up, while potentially showing control of the weed seeds themselves. The proof of concept as a result confirmed previously conducted third-party trials.
The successful proof of concept validates the firms natural approach to controlling unwanted pests and diseases. The proprietary formula, which utilizes the natural defence mechanism within mustard seed, has now proven itself as both a bio-pesticide and a bio-herbicide. The company is now in the process of conducting larger trials to reconfirm efficacy, application rates and overall length of control. These trials are expected to be completed by the end of the year.
“The developing characteristics of our active ingredient as a non-selective bio-herbicide represent a key application of our remarkable natural mustard-based technology. We are excited to potentially provide a natural solution for not only farmers but for home and garden use as well.”
Corey Giasson, CEO of MustGrow Biologics
The global herbicides market is currently estimated at over $24.6 billion as of 2018, while expected to grow by $8.9 billion through to 2023. This market was also the dominant crop protection category, accounting for approximately 42.7% of all crop protection sales in 2018.
Sponsored · Cambria Gold Mines
MustGrow Biologics last traded at $0.38 on the CSE.
FULL DISCLOSURE: MustGrow Biologics Corp is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover MustGrow Biologics Corp on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
